PRME · Prime Medicine Inc. Common Stock
View on chartInsiders & Stakes
| David R. Liu 10% Owner | ▲ Buy | Open Market | 20,240,945 Shares held | 6/30/2025 | View profile |
| Robert Nelsen Director | ▲ Buy | Open Market | 6,230,300 Shares held | 8/1/2025 | View profile |
| ARCH Venture Partners XII, LLC 10% Owner | ▲ Buy | Open Market | 6,230,300 Shares held | 8/1/2025 | View profile |
| ARCH Venture Partners X, LLC 10% Owner | ▲ Buy | Open Market | 6,230,300 Shares held | 8/1/2025 | View profile |
| Cahill Thomas Director | ▲ Buy | Open Market | 5,305,679 Shares held | 10/24/2022 | View profile |
| FMR LLC | ▼ Sell | Other | 4,228,589 Shares held | 10/24/2022 | View profile |
| GV 2021 GP, L.L.C. | ▲ Buy | Open Market | 3,262,440 Shares held | 8/1/2025 | View profile |
| Gottesdiener Keith Michael See Remarks | ▼ Sell | Gift | 682,259 Shares held | 10/8/2024 | View profile |
| Allan Reine Chief Executive Officer | ▲ Buy | Open Market | 125,000 Shares held | 5/21/2025 | View profile |
| Ann L. Lee Chief Technical Officer | ▲ Buy | Open Market | 100,000 Shares held | 5/21/2025 | View profile |
| Richard Brudnick Chief Business Officer | ▲ Buy | Open Market | 20,000 Shares held | 5/20/2025 | View profile |
Transaction History
| GV 2021 GP, L.L.C. | ▲ Buy | Open Market | 1,500,000 | $5.0M | 8/1/2025 |
| Robert Nelsen | ▲ Buy | Open Market | 3,030,300 | $10.0M | 8/1/2025 |
| ARCH Venture Partners XII, LLC | ▲ Buy | Open Market | 3,030,300 | $10.0M | 8/1/2025 |
| ARCH Venture Partners X, LLC | ▲ Buy | Open Market | 3,030,300 | $10.0M | 8/1/2025 |
| David R. Liu | ▲ Buy | Open Market | 21,000 | $53K | 6/30/2025 |
| David R. Liu | ▲ Buy | Open Market | 21,000 | $45K | 6/23/2025 |
| David R. Liu | ▲ Buy | Open Market | 21,000 | $31K | 6/16/2025 |
| David R. Liu | ▲ Buy | Open Market | 21,000 | $34K | 6/11/2025 |
| Ann L. Lee | ▲ Buy | Open Market | 100,000 | $113K | 5/21/2025 |
| Allan Reine | ▲ Buy | Open Market | 125,000 | $147K | 5/21/2025 |
| Richard Brudnick | ▲ Buy | Open Market | 20,000 | $24K | 5/20/2025 |
| Gottesdiener Keith Michael | ▼ Sell | Gift | 226,925 | $0 | 10/8/2024 |
| Gottesdiener Keith Michael | ▼ Sell | Gift | 226,925 | $0 | 10/8/2024 |
| Gottesdiener Keith Michael | ▼ Sell | Gift | 250,000 | $0 | 6/5/2024 |
| Gottesdiener Keith Michael | ▼ Sell | Gift | 250,000 | $0 | 6/5/2024 |
| ARCH Venture Partners X, LLC | ▲ Buy | Open Market | 3,200,000 | $20.0M | 2/15/2024 |
| Robert Nelsen | ▲ Buy | Open Market | 3,200,000 | $20.0M | 2/15/2024 |
| ARCH Venture Partners XII, LLC | ▲ Buy | Open Market | 3,200,000 | $20.0M | 2/15/2024 |
| Gottesdiener Keith Michael | ▼ Sell | Gift | 5,000 | $0 | 11/11/2023 |
| Gottesdiener Keith Michael | ▼ Sell | Gift | 7,500 | $0 | 11/11/2023 |
| David R. Liu | ▼ Sell | Gift | 1,000,000 | $0 | 7/21/2023 |
| David R. Liu | ▼ Sell | Other | 321,665 | — | 10/24/2022 |
| FMR LLC | ▼ Sell | Other | 423,509 | — | 10/24/2022 |
| FMR LLC | ▼ Sell | Other | 3,805,080 | — | 10/24/2022 |
| FMR LLC | ▼ Sell | Other | 98,967 | — | 10/24/2022 |
| Cahill Thomas | ▼ Sell | Other | 4,905,679 | — | 10/24/2022 |
| FMR LLC | ▼ Sell | Other | 11,015 | — | 10/24/2022 |
| Robert Nelsen | ▲ Buy | Open Market | 400,000 | $6.8M | 10/24/2022 |
| Robert Nelsen | ▲ Buy | Open Market | 400,000 | $6.8M | 10/24/2022 |
| Robert Nelsen | ▼ Sell | Other | 16,080 | — | 10/24/2022 |
| Cahill Thomas | ▲ Buy | Open Market | 400,000 | $6.8M | 10/24/2022 |
| FMR LLC | ▼ Sell | Other | 4,124,375 | — | 10/24/2022 |
| ARCH Venture Partners X, LLC | ▼ Sell | Other | 5,728,297 | — | 10/24/2022 |
| ARCH Venture Partners X, LLC | ▲ Buy | Open Market | 400,000 | $6.8M | 10/24/2022 |
| ARCH Venture Partners X, LLC | ▲ Buy | Open Market | 400,000 | $6.8M | 10/24/2022 |
| Robert Nelsen | ▼ Sell | Other | 5,728,297 | — | 10/24/2022 |
| Robert Nelsen | ▼ Sell | Other | 5,728,297 | — | 10/24/2022 |
| ARCH Venture Partners X, LLC | ▼ Sell | Other | 5,728,297 | — | 10/24/2022 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Prime Medicine stock surges after FDA clears IND for PM647
Prime Medicine shares rose significantly after the U.S. FDA cleared the Investigational New Drug application for PM647, a gene editing therapy for alpha-1 antitrypsin deficiency. This regulatory approval allows the company to begin clinical trials for the treatment. The positive news for Prime Medicine occurred alongside a broader decline in gene-editing stocks triggered by recent developments involving Anthropic AI.
Prime Medicine stock surges after FDA clears IND for PM647. Prime Medicine shares rose significantly after the U.S. FDA cleared the Investigational New Drug application for PM647, a gene editing therapy for alpha-1 antitrypsin deficiency. This regulatory approval allows the company to begin clinical trials for the treatment. The positive news for Prime Medicine occurred alongside a broader decline in gene-editing stocks triggered by recent developments involving Anthropic AI.